Top Page
Sarepta Therapeutics
(NASDAQ:SRPT)
Sarepta Therapeutics (SRPT) vs. SPDR S&P 500 ETF (SPY)
Sarepta Therapeutics Business Overview & Revenue Model
Sarepta Therapeutics Earnings Call Summary
Sarepta Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41B | 1.90B | 1.24B | 933.01M | 701.89M | 540.10M |
| Gross Profit | 1.82B | 1.58B | 1.09B | 793.02M | 604.84M | 476.72M |
| EBITDA | -186.59M | 333.06M | -439.20M | -582.12M | -306.08M | -453.38M |
| Net Income | -271.51M | 235.24M | -535.98M | -703.49M | -418.78M | -554.13M |
Balance Sheet | ||||||
| Total Assets | 3.49B | 3.96B | 3.26B | 3.13B | 3.15B | 2.98B |
| Cash, Cash Equivalents and Short-Term Investments | 850.99M | 1.35B | 1.68B | 1.99B | 2.12B | 1.94B |
| Total Debt | 1.25B | 1.34B | 1.40B | 1.62B | 1.14B | 1.07B |
| Total Liabilities | 2.17B | 2.44B | 2.41B | 2.74B | 2.22B | 2.22B |
| Stockholders Equity | 1.32B | 1.53B | 859.34M | 384.95M | 928.01M | 761.76M |
Cash Flow | ||||||
| Free Cash Flow | -381.10M | -342.74M | -588.34M | -356.17M | -481.66M | 25.26M |
| Operating Cash Flow | -244.64M | -205.79M | -500.99M | -325.35M | -443.17M | 107.47M |
| Investing Cash Flow | 737.55M | 755.56M | -165.80M | -1.05B | 495.41M | -121.72M |
| Financing Cash Flow | -80.14M | 124.81M | 125.00M | 232.51M | 561.57M | 682.32M |
Sarepta Therapeutics Technical Analysis
Sarepta Therapeutics Risk Analysis
Sarepta Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $2.94B | ― | -28.17% | ― | 129.21% | 80.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.58B | ― | -21.37% | ― | 47.15% | -311.26% | |
46 Neutral | $1.51B | -148.63 | ― | ― | 45.38% | 92.85% | |
45 Neutral | $2.01B | ― | -18.96% | ― | 191.53% | 5.09% | |
43 Neutral | $3.06B | ― | -60.66% | ― | ― | -2.75% | |
37 Underperform | $1.97B | ― | -95.40% | ― | ― | 4.68% |
Sarepta Therapeutics Corporate Events
Sarepta Therapeutics Inc. recently held its earnings call, presenting a balanced view of its financial and operational performance. The company highlighted significant achievements in revenue and study completions, while also addressing challenges such as the ESSENCE trial missing statistical significance and disruptions from paused shipments.
Sarepta Therapeutics Inc., a leader in precision genetic medicine, specializes in developing therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). The company recently announced its third-quarter 2025 financial results, highlighting the completion of its ESSENCE study, which evaluated the efficacy and safety of AMONDYS 45 and VYONDYS 53 in treating DMD. Despite the study not achieving statistical significance on its primary endpoint, it showed positive trends favoring the therapies, especially when excluding COVID-impacted data.
Study Overview: Sarepta Therapeutics Inc. is conducting a long-term multicenter prospective observational study titled A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice. The study aims to evaluate the effectiveness and safety of delandistrogene moxeparvovec, a gene transfer therapy, compared to standard care in patients with Duchenne Muscular Dystrophy (DMD). This study is significant as it seeks to provide insights into real-world outcomes of gene therapy in DMD treatment.
Study Overview: The study titled ‘A Two-Part, Open-Label Systemic Gene Delivery Study to Evaluate the Safety and Expression of RO7494222 (SRP-9001) in Subjects Under the Age of Four With Duchenne Muscular Dystrophy’ aims to assess the safety and expression of a gene therapy in young children with Duchenne Muscular Dystrophy (DMD). This research is significant as it targets a critical age group for early intervention in a progressive and debilitating condition.
Study Overview: Sarepta Therapeutics Inc. is conducting a long-term observational study titled ‘A Long-term Observational Study Evaluating Sarepta Therapeutics, Inc.’s Exon-Skipping Therapies in Patients With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice.’ The study aims to evaluate the real-world outcomes of exon-skipping therapies, specifically eteplirsen, golodirsen, and casimersen, in patients with Duchenne Muscular Dystrophy (DMD). This research is significant as it seeks to gather comprehensive data on treatment effectiveness in routine clinical settings, potentially influencing future therapeutic strategies.
Study Overview: The clinical study titled ‘An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in Association With Imlifidase in Subjects With Duchenne Muscular Dystrophy With Pre-existing Antibodies to rAAVrh74’ aims to assess the safety and efficacy of the gene therapy delandistrogene moxeparvovec (SRP-9001) when used alongside imlifidase. This study is significant as it targets Duchenne Muscular Dystrophy (DMD) patients who have pre-existing antibodies to the viral vector used in the therapy, potentially expanding treatment options for this group.
Study Overview: Sarepta Therapeutics Inc. is conducting a Phase 3, long-term follow-up study titled ‘A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study.’ The study aims to monitor the long-term safety and efficacy of delandistrogene moxeparvovec in participants with Duchenne Muscular Dystrophy who received the treatment in a previous clinical study. This research is significant as it seeks to provide a consistent approach to evaluating long-term outcomes, contributing valuable data to the understanding of the treatment’s impact.
Sarepta Therapeutics Inc. recently held its earnings call, revealing a mixed sentiment characterized by strategic restructuring and cost-saving measures aimed at bolstering the company’s financial health and future growth. Despite these positive steps, challenges such as workforce reductions, hesitancy in the adoption of ELEVIDYS, and the suspension of nonambulatory ELEVIDYS shipments pose significant hurdles for the company.
On August 20, 2025, Sarepta Therapeutics entered into exchange agreements with holders of its 1.25% Convertible Senior Notes due 2027, exchanging $700 million of these notes for new 4.875% Convertible Senior Notes due 2030, common stock, and cash. This strategic financial move, completed on August 28, 2025, aims to manage debt maturity and optimize capital structure, potentially impacting the company’s financial flexibility and market positioning.
The most recent analyst rating on (SRPT) stock is a Sell with a $12.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
On August 20, 2025, Sarepta Therapeutics entered into exchange agreements with holders of its 1.25% Convertible Senior Notes due 2027, exchanging approximately $700 million of these notes for new 4.875% Convertible Senior Notes due 2030, shares of common stock, and cash. Additionally, the company engaged in a private placement transaction with J. Wood Capital Advisors LLC for $20 million in common stock, with the issuance of these securities relying on exemptions from registration under the Securities Act. These strategic financial maneuvers are expected to impact the company’s capital structure and provide flexibility in managing its debt obligations.
The most recent analyst rating on (SRPT) stock is a Hold with a $20.50 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
Sarepta Therapeutics announced a strategic restructuring and pipeline prioritization, resulting in the end of Bilal Arif’s employment as Executive Vice President, Chief Technical Operations Officer, effective September 16, 2025. Arif will transition to a Special Advisor role until his employment ends and will continue as a consultant through December 31, 2025. The company has agreed to provide Arif with a severance package and consulting fees, while his equity awards will continue to vest during his consultancy. This move reflects Sarepta’s ongoing efforts to optimize its operations and focus on its core strategic objectives.
The most recent analyst rating on (SRPT) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapy for rare diseases, particularly Duchenne muscular dystrophy. In its latest earnings report, Sarepta Therapeutics reported a significant increase in total revenues for the second quarter of 2025, reaching $611.1 million compared to $362.9 million in the same period last year. This growth was primarily driven by the strong performance of its ELEVIDYS gene therapy product, which saw a substantial rise in sales. Despite the revenue growth, the company reported a net loss of $250.6 million for the first half of 2025, attributed to increased research and development expenses and strategic investments, including a significant upfront payment to Arrowhead Pharmaceuticals. Looking ahead, Sarepta’s management remains optimistic about its financial health, supported by its cash reserves and strategic collaborations, as it continues to focus on expanding its product pipeline and addressing safety concerns related to ELEVIDYS.